Literature DB >> 34950392

Nonepileptic Myoclonus in COVID-19: Case Report.

Henly Hewan1, Annie Yang2, Aparna Vaddiparti3, Benison Keung4.   

Abstract

In late 2019, the novel coronavirus, SARS-CoV-2, and the disease it causes, COVID-19, was identified. Since then many different neurological manifestations of COVID-19 have been well reported. Movement abnormalities have been rarely described. We report here a critically ill patient with COVID-19 who developed generalized myoclonus during the recovery phase of the infection. Myoclonus was associated with cyclical fevers and decreased alertness. Movements were refractory to conventional anti-epileptic therapies. There was concern that myoclonus could be part of a post-infectious immune-mediated syndrome. The patient improved fully with a 4-day course of high-dose steroids. Our experience highlights a rare, generalized myoclonus syndrome associated with COVID-19 that may be immune-mediated and is responsive to treatment.
© The Author(s) 2021.

Entities:  

Keywords:  COVID-19; immune-mediated; myoclonus; post-infectious

Year:  2021        PMID: 34950392      PMCID: PMC8689525          DOI: 10.1177/19418744211004315

Source DB:  PubMed          Journal:  Neurohospitalist        ISSN: 1941-8744


  12 in total

1.  Acute hypokinetic-rigid syndrome following SARS-CoV-2 infection.

Authors:  Antonio Méndez-Guerrero; María Isabel Laespada-García; Adolfo Gómez-Grande; Mariano Ruiz-Ortiz; Víctor Antonio Blanco-Palmero; Francisco Javier Azcarate-Diaz; Pablo Rábano-Suárez; Eva Álvarez-Torres; Carlos Pablo de Fuenmayor-Fernández de la Hoz; Diana Vega Pérez; Raquel Rodríguez-Montalbán; Alfredo Pérez-Rivilla; Javier Sayas Catalán; Ana Ramos-González; Jesús González de la Aleja
Journal:  Neurology       Date:  2020-07-08       Impact factor: 9.910

2.  Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China.

Authors:  Ling Mao; Huijuan Jin; Mengdie Wang; Yu Hu; Shengcai Chen; Quanwei He; Jiang Chang; Candong Hong; Yifan Zhou; David Wang; Xiaoping Miao; Yanan Li; Bo Hu
Journal:  JAMA Neurol       Date:  2020-06-01       Impact factor: 18.302

Review 3.  Encephalitis lethargica: 100 years after the epidemic.

Authors:  Leslie A Hoffman; Joel A Vilensky
Journal:  Brain       Date:  2017-08-01       Impact factor: 13.501

Review 4.  Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review.

Authors:  Adeel S Zubair; Lindsay S McAlpine; Tova Gardin; Shelli Farhadian; Deena E Kuruvilla; Serena Spudich
Journal:  JAMA Neurol       Date:  2020-08-01       Impact factor: 18.302

Review 5.  The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system.

Authors:  Francesca Coperchini; Luca Chiovato; Laura Croce; Flavia Magri; Mario Rotondi
Journal:  Cytokine Growth Factor Rev       Date:  2020-05-11       Impact factor: 7.638

6.  Neurological manifestations of COVID-19 and other coronavirus infections: A systematic review.

Authors:  V Montalvan; J Lee; T Bueso; J De Toledo; K Rivas
Journal:  Clin Neurol Neurosurg       Date:  2020-05-15       Impact factor: 1.876

Review 7.  Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology.

Authors:  Rudragouda Channappanavar; Stanley Perlman
Journal:  Semin Immunopathol       Date:  2017-05-02       Impact factor: 9.623

8.  Generalized myoclonus in COVID-19.

Authors:  Pablo Rábano-Suárez; Laura Bermejo-Guerrero; Antonio Méndez-Guerrero; Javier Parra-Serrano; Daniel Toledo-Alfocea; Daniel Sánchez-Tejerina; Teresa Santos-Fernández; María Dolores Folgueira-López; Judit Gutiérrez-Gutiérrez; Blanca Ayuso-García; Jesús González de la Aleja; Julián Benito-León
Journal:  Neurology       Date:  2020-05-21       Impact factor: 9.910

9.  Guillain-Barré Syndrome Associated with SARS-CoV-2.

Authors:  Gianpaolo Toscano; Francesco Palmerini; Sabrina Ravaglia; Luigi Ruiz; Paolo Invernizzi; M Giovanna Cuzzoni; Diego Franciotta; Fausto Baldanti; Rossana Daturi; Paolo Postorino; Anna Cavallini; Giuseppe Micieli
Journal:  N Engl J Med       Date:  2020-04-17       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.